Pan-PDE4 inhibitors, such as rolipram, have been used to reduce tumor necrosis factor (TNF) levels and neutrophil accumulation in models of systemic inflammation and CNS injury, such as SCI, cerebral ischemia and TBI [10, 12, 13, 20]. This evidence concerns the gene PDE4A and Cerebral ischemia.